CF PharmTech, Inc engages in the research, development, production and sale of respiratory diseases pharmaceutical products. The company is headquartered in Suzhou, Jiangsu and currently employs 574 full-time employees. The company went IPO on 2025-10-08. The Company’s product portfolio primarily focused on respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The firm's primary products include CF017, a budesonide suspension for inhalation targeting bronchial asthma, and CF018, an azelastine hydrochloride and fluticasone propionate nasal spray approved for allergic rhinitis. The firm mainly conducts its business in the domestic market.
02652.HK stock price ended at $35 on 星期一, after rising 5.29%
On the latest trading day Jan 19, 2026, the stock price of 02652.HK rose by 5.29%, climbing from $34.26 to $35.00. During the session, the stock saw a volatility of 6.47%, with prices oscillating between a daily low of $33.06 and a high of $35.20. Notably, trading volume dropped by 109.5K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 227.5K shares were traded, equating to a market value of approximately $10.5B.